Clinical Endoscopy

  • 제55권5호
  • /
  • Pages.630-636
  • /
  • 2022
  • /
  • 2234-2400(pISSN)
  • /
  • 2234-2443(eISSN)
대한소화기내시경학회 (The Korean Society of Gastrointestinal Endoscopy)
권호 표지
DOI QR코드

DOI QR Code

Safe implementation of transoral incisionless fundoplication as a new technique in a tertiary care center

  • Shivanand Bomman (Center for Digestive Health, Virginia Mason Franciscan Health) ;
  • Sofya Malashanka (Center for Digestive Health, Virginia Mason Franciscan Health) ;
  • Adil Ghafoor (Center for Digestive Health, Virginia Mason Franciscan Health) ;
  • David J. Sanders (Center for Digestive Health, Virginia Mason Franciscan Health) ;
  • Shayan Irani (Center for Digestive Health, Virginia Mason Franciscan Health) ;
  • Richard A. Kozarek (Center for Digestive Health, Virginia Mason Franciscan Health) ;
  • Andrew Ross (Center for Digestive Health, Virginia Mason Franciscan Health) ;
  • Michal Hubka (Center for Digestive Health, Virginia Mason Franciscan Health) ;
  • Rajesh Krishnamoorthi (Center for Digestive Health, Virginia Mason Franciscan Health)
  • 투고 : 2021.11.10
  • 심사 : 2022.01.17
  • 발행 : 2022.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Transoral incisionless fundoplication (TIF) is an accepted anatomic treatment for gastroesophageal reflux disease in selected patients. In this report, we analyze our institution's programmatic allocation of resources during the safe implementation of TIF as a new procedure. Methods: A retrospective analysis of all patients who underwent TIF from January 2020 to February 2021 at our institution was performed. The process of initially allocating the operating room (OR) with overnight admission and postoperative esophagram for added safety, and subsequently transitioning TIF to the endoscopy suite (ES) as an outpatient procedure was described. Patient safety and outcomes were evaluated during transition. Results: Thirty patients who underwent TIF were identified. The mean age was 51.2±16.0 years. TIF was performed in an OR in nine patients (30%) and 21 (70%) in the ES. All the OR patients were admitted overnight and had routine esophagogram. In contrast, four (19%) from the ES group required clinically-indicated admission and three (14.2%) required esophagram. The mean procedure duration was significantly lower in the ES group (65.7 min vs. 84 min, p=0.02). Conclusions: A stepwise, resource-efficient process was described that allowed safe initiation of TIF as a new technique and its effective transition to a fully outpatient procedure.

키워드

참고문헌

  1. Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019;156:254-272.  https://doi.org/10.1053/j.gastro.2018.08.063
  2. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005;3:543-552.  https://doi.org/10.1016/S1542-3565(05)00153-9
  3. Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. JAMA 2020;324:2536-2547.  https://doi.org/10.1001/jama.2020.21360
  4. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med 2014;371:836-845.  https://doi.org/10.1056/NEJMra1314704
  5. Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology 2018;154:302-318.  https://doi.org/10.1053/j.gastro.2017.07.049
  6. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010;32:720-737.  https://doi.org/10.1111/j.1365-2036.2010.04406.x
  7. Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010;32:1124-1128.  https://doi.org/10.1111/j.1365-2036.2010.04453.x
  8. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011-1019.  https://doi.org/10.1038/ajg.2012.108
  9. Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol 2009;25:352-357.  https://doi.org/10.1097/MOG.0b013e32832ad8b4
  10. Trad KS, Barnes WE, Prevou ER, et al. The TEMPO trial at 5 years: transoral fundoplication (TIF 2.0) is safe, durable, and cost-effective. Surg Innov 2018;25:149-157.  https://doi.org/10.1177/1553350618755214
  11. Toomey P, Teta A, Patel K, et al. Transoral incisionless fundoplication: is it as safe and efficacious as a Nissen or Toupet fundoplication? Am Surg 2014;80:860-867.  https://doi.org/10.1177/000313481408000918
  12. Richter JE, Kumar A, Lipka S, et al. Efficacy of laparoscopic nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis. Gastroenterology 2018;154:1298-1308.  https://doi.org/10.1053/j.gastro.2017.12.021
  13. Ihde GM. The evolution of TIF: transoral incisionless fundoplication. Therap Adv Gastroenterol 2020;13:1756284820924206. 
  14. Chang KJ, Bell R. Transoral incisionless fundoplication. Gastrointest Endosc Clin N Am 2020;30:267-289.  https://doi.org/10.1016/j.giec.2019.12.008
  15. Brewer Gutierrez OI, Dbouk M, Kannadath BS, et al. Mo1283 Learning curve of transoral incisionless fundoplication: a single endoscopist experience. Gastrointest Endosc 2020;91Suppl:AB416.